Krause,'
Franz Dienstl,3 and Bernd Puschendorf2' 4 With a new immunoenzymometric assay we measured human glycogen phosphorylase isoenzyme BB (GPBB) in 116 healthy individuals, 14 patients with stable angina, 107 nontraumatic chest pain patients on admission to the emergency department [45 acute myocardial infarction (AMI), 49 unstable angina, 13 other diseases], and in serial samples from 41 AMI patients. GPBB was compared with creatine kinase (CK), CKMB mass, myoglobin, and cardiac troponin T. Receiver-operating characteristic plots demonstrated the significantly greater (P O.012) discriminatory power of GPBB to detect acute ischemic coronary syndromes compared with all other tested markers. GPBB was the most sensitive marker for detection of AMI during the first 4 h after onset of chest pain, and only GPBB was increased above the upper reference limit (7 g/L) on admission in patients who had unstable angina at rest and reversible ST-T alterations. This and the high early sensitivity of GPBB are most likely explained by its function as a key enzyme of glycogenolysis.
Indexing Terms: myocardial infarction/unstable angina pectoris/creatine kinase/myoglobin/troponin T Early identification and confirmation of acute myocardial infarction (AMI) is essential for correct patient care and disposition decisions (1 )5 Because as many as one-fourth of AMI patients present with atypical signs and symptoms (1, 2) , -5% of patients with AMI are released unintentionally from the emergency department, which places them at greater risk of morbidity and mortality resulting from complications (2) . Although electrocardiography (ECG) is considered the most simple, convenient, reliable, and reproducible method for early diagnosis of AMI, approximately half of all AMI patients have nondiagnostic
ECGs at the time of presentation to the emergency department (1, 2) . Creatine kinase (CK) and CKMB activities traditionally have not been considered helpful in the emergency evaluation of the patient with chest discomfort (3) . The search for more sensitive biochemical markers to indicate acute myocardial ischemia during its early phase (3, 4) reflects the need for an improved initial diagnostic accuracy of these markers in patients with acute chest pain. In addition, biochemical markers may gain increasing importance for the noninvasive monitoring of the effectiveness of thrombolytic treatment (5) . Human glycogen phosphorylase (GP) b (EC 2.4.1.1), particularly its isoenzyme BB (GPBB), has a distinct sensitivity to myocardial oxygen deficiency in cardiomyocytes (6, 7) . There is evidence that GPBB is rapidly released into the circulation in the early phase of AMI (8, 9) as well as after perioperative myocardial infarction following coronary artery bypass grafting (10, 11) .
GP in mammals is known to have three major isoenzymes: BB (brain), Mlvi (muscle), and LL (liver) (12, 13) . GPBB is also found in heart muscle (14, 15) , including human myocardium (16) , where it is, besides the MM subtype, the predominant isoenzyme. The three isoenzymes can be distinguished by functional and immunological properties, and are also encoded by three distinct genes (17) . The cDNAs encoding human BB, MM, and LL isoenzymes of phosphorylase have been cloned and sequenced (17) . The protein sequence deduced from the nucleotide sequence of GPBB cDNA is 83% identical to muscle sequence and 80% identical to liver sequence (17) . However, the C-terminal portion of the BB isoenzyme has 21 and 16 additional amino acid residues, respectively, that are not present on the MM and LL isoenzymes, which makes this protein a promising analyte for isoenzyme specificity. Indeed, by using highly purified human BB antigen isolated from brain (17, 18) and heart tissue (8, 16) , sensitive immunoassay methods for measuring immunoreactive GPBB have been established (8, 18, 19) .
As a key enzyme of glycogenolysis, cardiac GP is a constituent of the particular sarcoplasmic reticulum
Subjects and Methods
The procedures followed were in accordance with the Helsinki Declaration of 1975, as revised 1983.
Subjects

Healthy
individuals.
GPBB was measured in the plasma of 40 apparently healthy blood donors, 46 coworkers, and 30 healthy individuals seen for routine medical examination. This reference population comprised 59 men and 57 women, ages 20 to 66 years (mean 40 years). A single blood sample was drawn from each subject.
Chronic stable angina pectoris patients.
This group comprised 14 patients [11 men, 3 women, age 54 ± 9 years (mean ± SD); range 47-64 years] with chronic stable angina who underwent percutaneous coronary angioplasty. A single blood sample was obtained before the angioplasty.
AMI patients.
The object of this part of our study was to identifr existing differences in the time courses of GPBB and other biochemical markers in plasma after AMI. We investigated 41 patients with AMI (30 men, 11 women, mean age 59 ± 11 years; range 36-79 years) who gave informed consent for extra blood samples to be drawn.
World Health Organization (WHO) criteria were followed for the diagnosis of AMI (29, 30). On average, patients were admitted to the coronary care unit 5 h (range 0.5-27.5 h) after the onset of chest pain. Peripheral venous blood samples were collected from an indwelling catheter or by venipuncture before therapy was started in the coronary care unit, hourly for the first 10 h, then every 4 h up to 24 h after admission to the hospital; in 8-h intervals for the subsequent 24 h; and then daily until the patient's discharge. Patient care requirements occasionally prevented the taking of a sample. Twenty-one patients sustained an anterior and 20 an inferior wall AMI (32 Q-wave and 9 non-Q-wave AMI Acute coronary angiography (CAG) was not routinely performed in the patients investigated.
To determine whether there was successful reperfusion of the infarct-related coronary artery in Q-wave AMIs, we used four biochemical criteria that had been evaluated previously by using acute CAG as the criterion standard in AMI patients treated with thrombolytic agents within 6 h after the onset of chest pain (5, 29, 31, 32) . In the present study, early reperfusion of the infarct-related artery was assumed when the following biochemical criteria were fulfilled:
(a) CK peaks within 12 h; (b) CKMB peaks within 10 h; (c) myoglobin peaks within 3 h; and (d) cThT peaks within 15 h after administration of thrombolytic treatment (5). In 25 Q-wave AMI patients who were treated within 6 h from the onset of symptoms, data were complete. Of these patients, 18 met these noninvasive criteria for reperfl.ision and were classified as "early reperfused." CAG was performed selectively in 18 patients at a mean of 22 days (range 4-44) after AMI.
Nontraumatic chest pain patients.
This part of our study evaluated the diagnostic performance of GPBB for the early diagnosis of acute ischemic coronary syndromes defined as AMI and severe unstable angina at rest in emergency room patients with chest pain as their major symptom.
The study population of 107 patients (75 men, 32 women; mean age 61 ± 12; range 29-89 years) therefore did not include cases of chest contusion or trauma. The mean delay from the onset of chest pain to admission was 4.7 h (range 0.3-48). Forty-five patients were subsequently determined to have had an AMI (according to WHO criteria), 24 Q-wave and 21 non-Q-wave.
Forty-nine patients presented with unstable angina, 17 with severe chest pain and transient ST-T alterations at rest. A further 13 patients had chest pain not related to coronary artery disease (CAD; 2 cases of supraventricular tachycardia, 4 pneumonia with pleurisy, 1 heart failure with pul-monary edema, 3 musculoskeletal disorders, 1 pulmonary embolism, and 2 perimyocarditis).
In these patients a single blood sample was drawn immediately after admission. All patients received routine emergency treatment.
All AMI patients were transferred to the coronary care unit before initiating thrombolytic treatment.
None of these patients had received thrombolytic therapy before admission to the hospital.
Diagnostic Criteria for Classification of Patients
Patients were classified as AMI, unstable angina, stable angina, and patients without CAD (angina could be excluded by a definitive alternative source of chest pain). An acute ischemic coronary syndrome was defined as AMI or severe unstable angina at rest together with transient ST-or T-wave alterations.
The EDTA-plasma from healthy subjects, which was used as zero-plasma for the preparation of controls in IEMA, was purchased from the public blood donation center in Berlin. Routinely, the basal concentration of GP was eliminated by affinity chromatography with 5'-AMP-Sepharose 4B. Antigen preparation.
The b form of GPBB was isolated and purified from human heart muscle tissue as previously described (16, 33) with slight modifications. In short, heart muscle tissue (-100 g of material taken <10 h postmortem at autopsy) was homogenized in 2.5-fold volume of extraction solution (1 mmol,'L EDTA, 30 nimol/L 2-mercaptoethanol, 5 mmolIL glycero-2-phosphate, pH 6.8) and centrifuged at 20 000g at 0 #{176}C. The supernate was incubated at 37 #{176}C for 45 mm; the protein was precipitated at 4 #{176}C by addition of ammonium sulfate (16) ; and the pellet was suspended, dialyzed, and subjected to starch gel column chromatography (33). The pooled GPBB isoenzyme fraction was further purified and concentrated by affinity chromatography on 5'-AMP-Sepharose 4B (34). The antigen was stored in 500 mIJL glycerol at -20 #{176}C. GPBB enzyme activity was assayed by using an immunoinhibition test previously described by Rabitzsch et al. (8) . peroxidase) was selected for the development of the onestep IEMA for GPBB.
IEMA.
The IEMA for GPBB was performed on microtiter plates. mAb1 was diluted in a solution containing 20 mmol/L potassium hydrogen phosphate, 20 mmol/L potassium dihydrogen phosphate, and 150 mmol/L sodium chloride (PBS, pH 7.3). Peroxidaseconjugated mAb2 was diluted in PBS containing 0.5 mIJL Tween 20 and 100 mIJL calf serum. For coating, 100 LIwell of mAb1 (7.5 mgfL) was added to polystyrene microtiter plates and incubated at 37 #{176}C for 16-18 h. All following steps of the assay were performed at room temperature.
The dried plates were washed three times with washing solution [0.5 mLIL Tween 20 in water (Tw-water)]
and again filled with 200 jLIwell of blocking solution (5 g/L bovine serum albumin, 0.5 mIlL Tween 20 in PBS) for blocking nonspecific protein binding sites. After shaking for 1 h, plates were emptied and washed three times with Tw-water. Then 50 L of human zero-plasma as blank (n = 4; see Materials), eight different calibrator samples in duplicate containing 1.25-160 gfL GPBB in zero-plasma, and plasma samples of patients in duplicate were incubated with shaking in darkness for 90 mm together with 50 pL of peroxidase-conjugated mAb2 (0.2 tg/L). After washing the plates more than five times with Tw-water to remove the unbound free conjugate, the peroxidase reaction was started by adding to each emptied well 200 L of the substrate chromogen solutiom (0.4 g/L o-phenylenediamine and 0.015% hydrogen peroxide in 70 mmol/L citric acid and 100 mmolIL sodium phosphate, pH 5.0). The reaction was stopped after 15 mm by addition of 50 L of 2 mol/L sulfuric acid, and the absorbance was measured at 492 nm in a microplate reader (liT-Il; Anthos, Koln, Germany). GPBB values were calculated as micrograms of isoenzyme protein per liter of blood plasma.
Assay evaluation.
To validate the IEMA, we performed dilution assays, determined GPBB recovery, examined assay reproducibility, and determined crossreactivities with MM and LL isoenzymes by adding up to 100-fold greater concentrations of GPMM and GPLL in comparison with GPBB, i.e., plasma concentrations of 160-10 000 gIL. 
Results
Isolation of GPBB
The purified GPBB from human heart in the b form exhibited a specific activity of 30 kU/g protein. Of the total enzyme activity, >99% GPBB was obtained according to the immunoinhibition assay of the isoenzyme's activity (8) . On polyacrylamide slab gels, the purified GPBB presented a single band with detection of enzyme activity in the nondenaturing system (16) Characterization of mAbs Table 1 shows some of the characteristics of mAbs against GPBB produced by seven different hybridoma clones obtained from one fusion experiment.
All mAbs belong to the immunoglobulin class IgG i/K, except mAb 1G12, which is an IgG2a/K. The specificities of the mAbs regarding cross-reactivities with the isoenzymes MM and LL were tested by immunodot-ELISA with the antigen adsorbed to nitrocellulose.
None of the antibodies revealed any cross-reactivity in this assay. Some of the antibodies interfered with the enzyme activity of GPBB. The strongest inhibition was caused by the mAb IIID9 (see Table 1 ). Thus the recognized epitope should be located at or near the catalytic site of the GPBB molecule.
The screening of all possible mAb combinations by IEMA (the first mAb was adsorbed onto microtiter plates, the second one was fluorescein isothiocyanatelabeled) permitted the use of seven purified mAbs (49 different pairs) to define relative epitopes recognized by the corresponding mAb. As demonstrated in the last column of Table 1, five different antigenic determinants could be defined. Three of the mAbs (1G12, 11A2, and VD4) bind to the same epitope.
Assay Characteristics
The one-step sandwich IEMA of GPBB in human EDTA-plasma was performed by simultaneous incubation of both the immobilized mAb VID12 and the peroxidase-conjugated indicator mAb IIF11. Measuring range and specificity.
The assay enables a specffic and sensitive estimation of GPBB in the diagnostically relevant range of 0.5-200 gfL isoenzyme protein in EDTA-plasma.
The lower detection limit of the assay was 0.3 g/L (3 SD above the mean nonspecific binding of the reagent blank). The calibration curve of GPBB in human EDTA plasma, given in Fig. 1 , is linear throughout the total range of 0.625 to 160 gfL. The degree of cross-reactivity of the skeletal muscle (MM) and liver (LL) isophosphorylases with the Table 1 . CharacterizatIon of mAbs against GPBB. GPBB IEMA was investigated in plasma concentrations of 160-10 000 giL by addition of up to 100-fold excess concentrations of GPMM and GPLL compared with GPBB. On the basis of the sensitivity of the IEMA for GPBB (0.3 g/L), both isoenzymes showed a crossreactivity of <1% only (see Fig. 1B ), allowing the determination quantitatively of GPBB even in the presence of the other isoenzymes without any substantial interference.
Cross-
Immunoglobulin
Additionally, no cross-reactivity of the selected mAbs with isoenzymes MM and LL could be detected in the immunodot-ELISA (39) (see Subjects and Methods).
Linearity
and recovery. The analytical recovery was tested in a range of 15-120 g/L by addition of GPBB purified from human heart to human zero-plasma. We found a recovery of 105.5% ± 1.92% (mean ± SD; n = 10). The linearity was estimated by 2-, 4-, 8-, and 16-fold dilutions of a plasma sample from a patient with a high mass concentration of GPBB with a zeroplasma. The correlation coefficient calculated from expected and measured mass concentrations was r = 0.994 (y = 1.034x + 0.48).
Precision.
The within-run and between-run variations of the assay were calculated for a range of concentrations, starting from below the URL (7 g/L) to very high (2.5, 10, 40, and 160 g/L). The intraassay CVs were 5.1%, 4.0%, 5.2%, and 4.7% (n = 18), and the interassay CVs were 11.0%, 11.2%, 10.3%, and 6.0% (n <15 a = 16), respectively. Plasma GPBB (pg/L) Fig. 3 . GPBB mass concentrations in patients with CAD with and without acute ischemic coronary syndromes.
Frequency distribution of the highest measured plasma concentrations of GPBB in patients with acute ischemic coronanj syndromes (acute CAD:
unstable angina with ST-T alterations at rest and AMI; n = 58) and patients without acute ischemlc coronary syndromes (CAD: stable angina and unstable angina without ST-I alterations at rest; n = 45).
patients from 7 to 13 h after the onset of chest pain (Fig. 4B ). Early sensitivities of biochemical markers during the first 12 h after the onset of chest pain are compared in Fig. 4A . For example, 4 h after the onset of chest pain, GPBB was increased in 70%, myoglobin in 43%, cThT in 33%, and CKMB mass in 56% of patients.
The difference between GPBB and cTnT was significant (P = 0.04 1). Interestingly, although myoglobin was increased in all AMI patients investigated during the first 12 h after the onset of chest pain, we found no time point at which myoglobin was increased in all investigated patients at the same time, because either myoglobin was not yet increased in all patients (early period) or it had already returned to normal in some patients (late period).
100
Time after onset of chest pain, h 
GPBB (B).
Values were calculated as percentage of patients with marker concentrations above the URL at various times after onset of chest pain. The range of the 95% confIdence interval of GPBB during the first 12 h after the onset of chest pain is indicated as the shaded area (A). 
GPBB vs Other Biochemical Markers in AMP Patients
GPBB mass, myoglobin, cThT, CKMB mass concentrations, and CK activity of 18 AMI patients are compared in Fig. 6 . For this purpose, only AMI patients admitted 4 h after the onset of chest pain were included, because after 4 h the probability strongly increases that all four markers are increased already on admission. For better comparison of markers, concentrations are given as multiples of their URL. Criteria describing the time courses of biochemical markers are listed in Table 2 . GPBB is the first marker that increases to pathological concentrations in plasma after AMI. The difference between the first appearance of GPBB and all other markers was significant (P <0.05). Myoglobin showed the earliest peak values, which occurred significantly earlier than the peak values of the other markers (P <0.005) except for GPBB. The time to GPBB peak values differed significantly (P <0.05) from the time to peak values of CKMB, cTnT, and CK. Myoglobin was also the first marker that disappeared in plasma after AMI. The differences between myoglobin and the other markers were highly significant (P <0.0005). After AMI, cThT showed the highest relative increase of peak values compared with URL ( Table 2 ). The differences in the magnitudes of increase between cThT and myoglobin, CK, and GPBB were significant (P <0.05). GPBB peak values correlated closely with CKMB (r = 0.84, P = 0.0002) and myoglobin (r = 0.93, P = 0.0001) peaks.
We also compared the early sensitivity of biochemical markers in samples from AMI patients that were obtained before initiating thrombolytic treatment. Patients after cardiopulmonary resuscitation or directcurrent countershock therapy were also excluded from data analysis. The most striking feature of GPBB is itr high early diagnostic sensitivity.
During the first 4 1 after the onset of chest pain, GPBB was significantl3 (P <0.05) more frequently increased than all othei markers tested (Table 3) .
Diagnostic Performance of GPBB
The ROC curves of GPBB, CKMB mass, CK, and cThT for the discrimination between patients without and with acute ischemic coronary syndromes (unstable angina at rest with transient ST-T alterations and AMI) are shown in Fig. 7 . The GPBB ROC curve confirmed our URL in nontraumatic chest pain patients. The point on the plot with a 450 tangent and the greatest deviation from the diagonal line was 7 g/L. The position of two (6 and 9 gfL) other discrimination limits is also shown on the plot. With the use of 6 instead of 7 g/L the sensitivity increases but, not surprisingly, specificity decreases as well. The discriminatory power of GPBB to detect acute ischemic coronary syndromes in patients at admission to the emergency department is superior to all other markers tested (Fig. 7, Table 4 ). The area under the GPBB ROC curve, 0.91 (95% confidence interval, 0.85-0.97), was Various indicators describing the performance of a biochemical marker to diagnose acute ischemic coronary syndromes are listed in Table 4 . The URLs of markers were used as cutoff values for the calculation of the values listed in Table 4 . The distributions of GPBB mass, CKMB mass, CK, and cThT concentrations investigated in the blood of 107 patients on admission to the emergency room (Table 5) explain the  superiority of GPBB over the other tested markers for the diagnosis of acute coronary syndromes. This superiority is based on, first, GPBB's higher early sensitivity for AMI (Tables 3 and 5) , and second, its early increase in patients with unstable angina and transient ST-T alterations (Table 5 ). In the latter patients, GPBB was the only marker that was not only significantly higher (P = 0.0001) than in patients without ST-T changes, but was also increased above its URL in the majority of these patients even on admission to the emergency department (Table 5) . By contrast, CK activities, CKMB mass, and cTnT concentrations were still within the reference interval in most of these patients. The potential usefulness of GPBB for diagnosing and monitoring unstable angina is also demonstrated by Fig. 8 . This figure shows GPBB, CKMB mass, CK, myoglobin, and cTnT time courses of a typical patient with unstable angina at rest and ST-T alterations in whom we could obtain serial samples during his stay at the coronary care unit. 0.20 (0.12-0.34) GPBB showed multiple peaks and was the only marker with a substantial increase. In this patient GPBB peaks correlated with episodes of chest pain.
Discussion
Here we mainly describe the development and evaluation of a new assay for measuring human GPBB. We also summarize our first results of the clinical evaluation of the marker and review the pathophysiological background of GPBB. Clinical key features of the marker (early sensitivity for AM!, early release in patients with severe unstable angina pectoris) have already been published (9, 43). For the most part the subjects of previous investigations (9, 42, 43) were included in the larger patient populations of this study.
IEMA of GPBB
The mAb combination chosen allowed the development of a sensitive and specific IEMA for the detection of human GPBB. 6 The analytical sensitivity, crossreactivities with both other isoenzymes of GP, linearity, recovery, and precision of the assay are satisfactory. With this assay GPBB basal concentrations in healthy individuals and patients without acute ischemic heart disease were low, which is a prerequisite for a high diagnostic sensitivity.
We calculated a URL of 7 p.g/L for measurement of GPBB in EDTA-plasma of 116 healthy subjects. This limit could be confirmed in other reference populations such as patients with chronic stable angina pectoris and nontraumatic chest pain patients. The latter may be the ideal subjects to meet the demand for similarity of preanalytical conditions between patients and reference subjects, because they were hospitalized with chest pain but later proved not to have had an acute ischemic coronary syndrome.
6A modified GPBB test kit is commercially available from
Laboserv Diagnostica, Giessen, Germany. 
GPBB
GPBB as Marker of Ischemic Myocardial Injury
GP has three isoenzymes.
The presented GPBB IEMA does not show substantial cross-reactivity with other isoenzymes such as GPMM and GPLL (<1% each). Brain and myocardium are the only known tissues with considerable GPBB content (17, 18) and, therefore, increases in GPBB should be highly specific for ischemic myocardial injury when damage to the brain and consequent disturbance of the blood-brain barrier can be excluded. We found a high specificity of GPBB that was in the range of that of CKMB or cTnT in emergency department patients presenting with chest pain. This patient population was preselected, and, therefore, future studies on the diagnostic specificity of GPBB will also have to address the issue in an unselected cohort of patients that includes severely traumatized patients with and without head injuries and patients with liver damage or renal failure. However, the most striking and promising feature of GPBB is its high sensitivity for AMI during the very early hours after the onset of chest pain. For the first time we compared the early sensitivities of GPBB, CKMB mass, myoglobin, and cThT. The same patients were tested for all biochemical markers, which is a prerequisite for a good, reasonable comparison of concentration time courses of different markers. Our study population was not uniform (e.g., a mixed cohort of Q-wave and non-Q-wave AM!, some scatter in the delay from the onset of symptoms to admission, differences in the reperfusion status of the infarct-related coronary artery). Because we tested and compared all markers in the same AM! cohort, all these possible biases affect all biochemical markers tested in a similar manner; therefore, they may limit but do not qualitatively upset our results, which allow several important conclusions. This is highlighted by the fact that results and conclusions derived from samples drawn before thrombolytic therapy were identical.
Our study confirms that the sensitivity of conventional markers, including myoglobin, CKMB mass, and cTnT, is not sufficient during the first 2 h after the onset of chest pain (24, 25, 27, 44, 45) . However, there were distinct differences in sensitivities of GPBB in comparison with myoglobin, CKMB mass, CK, and cThT within the first 2 h after AM! onset, and in our patients GPBB was the most sensitive marker during the first 4 h after AM! onset. In contrast to all other markers tested, GPBB started to increase during the first 2 h after the onset of chest pain in the majority of AMI patients. Therefore, it may be a very important marker for the early diagnosis of AM!. However, this high early sensitivity requires the development of a rapid assay suitable for stat determination in the routine emergency laboratory. In addition, larger series of more uniform AMI patients must be investigated to confirm the diagnostic validity of GPBB before GPBB determination can be introduced as a part of the routine evaluation of patients with suspected AM! who are admitted within 3 h after the onset of chest pain. Similar to soluble markers such as myoglobin and CKMB (5), we could demonstrate that GPBB time courses in AM! patients are markedly influenced by whether early reperfusion of the infarct-related coronary artery occurs. The well-established "wash-out" phenomenon after successful thrombolysis leads to a more rapid increase in GPBB, with earlier and higher peak values. Therefore, GPBB may be useful, along with other soluble myocardial proteins (5), for assessing the effectiveness of thrombolytic therapy noninvasively. However, decision limits to detect successful and, clinically more important, failed reperfusion remain to be established in an acutely performed CAG controlled study. To determine the exact timing, character, and degree of reperfusion requires serial acute CAGs, which could not be done in this study. Our study reports preliminary data on the reperfusion-dependent release of GPBB after AM!.
GPBB application is not restricted to conventional AM!. As underlined by the ROC curve and ROC area calculations of GPBB and comparison with those of the other markers studied, GPBB showed the best diagnostic performance of all markers tested to detect acute ischemic coronary syndromes (AM!, or severe unstable angina at rest with transient ST-T alterations) on admission.
Previously, an increase in CKMB mass, myoglobin, and cTnT concentrations has been described in serially drawn blood samples of a subgroup of patients with unstable angina (46) (47) (48) (49) .
Confirming earlier results (43), we found an early release of GPBB in the blood of patients with unstable angina and transient ST-T alterations. In these patients GPBB was the only marker that was increased above its URL on admission to the emergency department. In the present study, the patients without ischemic heart disease and the healthy individuals represent the background GPBB plasma concentration, and the AM! patients represent the fall extent of GPBB release when there is irreversible cell damage. These are ideal reference groups for the study of GPBB concentrations in patients with angina pectoris. GPBB plasma concentrations in patients with chronic stable angina or unstable angina without ST-T changes at rest resembled those of healthy individuals or patients without angina. However, in patients with unstable angina at rest and transient ST-T alterations, we found an early release of GPBB. In addition, fluctuations of GPBB found in a patient with unstable angina in whom we could obtain serial samples correlated with evidence of repetitive ischemic episodes. GPBB may reflect the degree of myocardial damage. Whether GPBB release is due to minimal necrosis of myocardial tissue or severe reversible ischemic injury cannot be determined from the present study. In unstable angina a dynamic stenosis can cause unpredictive episodes of myocardial ischemia. Thus, the challenge is not always simply to rule AMI in or out, but rather to distinguish early the patients with acutely unstable coronary lesions from those with either stable coronary lesions or none. The results of the present study suggest that for this purpose GPBB may be superior to conventional markers, including myoglobin, CKMB mass, and cTnT. GPBB IEMA is a promising diagnostic tool, because it may help to determine the frequency and severity of myocardial ischemic events in the different coronary syndromes.
Myocardial Oxygen Deficiency and GPBB Release
The early release and the high diagnostic early sensitivity of GPBB for severe myocardial ischemia and AM! raise questions on the mechanisms of GPBB release from ischemic myocardium, particularly considering the higher molecular mass of GPBB (188 kDa as dimer) compared with myoglobin (17.8 kDa), cTnT (37 kDa), and CK (86 kDa as dimer). An essential part of a possible explanation may be its key role in the energy metabolism of ischemic myocardium. A substantial amount of phosphorylase activity in the heart muscle is normally associated with microsomal membranes together with glycogen particles (20, 21, (50) (51) (52) , an SR-glycogenolysis complex being assumed (21, 22) to represent a functionally coupled association. With isolated glycogen particles, a burst in glycogenolysis could be initiated by either calcium ions or cAMP (22) Indeed, cardiac glycogen breakdown was found to be continued during postischemic reperfusion when the a form of GP declined to preischemic control concentrations but the orthophosphate concentration was still high (55).
The first indication that GP can be released from damaged muscle tissue into blood was obtained from rabbit after removal of a tourniquet that had compressed the hind leg for several hours (56). An efflux of GP has been also observed in isolated perfused rabbit heart after interruption of perfusion (7, 23) . In conscious dogs a rapid release of GPBB and CKMB was measured in the cardiac lymph after a transient ligation of the coronary artery sb mm (6) . In these experiments as well as in patients with AM!, the released GPBB was exclusively found in the b form (6, 57) . Thus the activity of GPBB (form b) may catalyze the degradation of glycogen in the SR-glycogenolysis complex in the ischemic area of the myocardium (54, 58). When glycogen is broken down and disappears, GPBB becomes free to move from the pen-SR compartment directly into the extracellular fluid, if cell membrane permeability is simultaneously increased, which is usually the case in ischemia. A gradient in GPBB concentration, which immediately forms in this particular compartment of the SR-glycogenolytic complex (Fig. 9) , may be the reason for the GPBB (bfotm)
Blood plasma Fig. 9 . GPBB release from the cardiomyocyte in ischemia.
OP together with glycogen are tightly associated with the vesicles of SR under normal conditions. Release of GPBB, the main isoform in the myocardlum, essentially depends on the degradation of glycogen, which is catalyzed by GPa (the phosphorylated, active form of the isoenzyme) and GPb (nonphosphorylated, AMP-dependent form). lschernia is known to favor the conversion of bound GPb into GPa, thereby accelerating glycogen breakdown, which seems to be the ultimate prerequisite for getting OP into a soluble form. An efflux of GPBB into the extracellular fluid may follow only if ischemla-lnduced structural alterations In the cell membrane are manifested. P1, Inorganic phosphate; G-1-P, glucose 1-phosphate. For more details see Discussion.
'1 high efilux rate of GPBB, which, contrary to other cytosolc constituents, may be realized, at least partly, via T-tAibuli. The fact that the sensitive glycogen degradation regulated by Ca2, metabolic intermediates, nd catecholamines seems to be a crucial prerequisite for the efflu.x of GPBB thus underlines the specific sensitivity of this enzyme marker to indicate transient imbalances in heart energy metabolism, as is the case during angina pectoris attacks and (or) in the infarcting myocardium.
Whether an increase of GPBB may occur in response to therapeutic circumstances in which cardiac work is increased and glycogen might be mobilized, such as after administration of catecholamines and glucagon, is very unlikely so long as concomitant myocardial injury is not processed. In experimental data, even high doses of epinephrine did not cause a detectable GP release from cardiac myocytes without cell membrane damage (23).
In summary, we report a sensitive and specific IEMA for the determination of human GPBB. GPBB was the most sensitive biochemical marker of all tested (CK, CKMB mass, myoglobin, cTnT) in AM! patients during the first 4 h after the onset of chest pain. Application of GPBB is not restricted to conventional AM!. GPBB was markedly increased in the majority of patients with unstable angina and reversible ST-T changes even on admission. It may reflect, in time and degree, the range of ischemic damage in myocardial tissue. GPBB IEMA is a promising means of extending our knowledge of the severity of myocardial ischemic events in the various coronary syndromes. The high early sensitivity of GPBB for ischemic myocardial injury is probably explained by its function as a key enzyme of glycogenolysis.
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